The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of the study is to find out whether adding ianalumab to the usual treatment leads to a better disease response than placebo, using the SRI-4 score at week 60 as the main measure. Participants are randomly assigned to receive either the drug or placebo for about a year, with regular clinic visits for safety checks and disease assessments while they continue their regular medicines; the dose of steroids may be lowered if the disease improves.

Researchers will record how many participants show improvement in disease activity, avoid serious flare‑ups, and are able to reduce steroid use to 5 mg per day or less. They will also monitor for side effects and collect blood samples to check drug levels and any immune reaction against the drug. The study ends after the 60‑week treatment period, followed by a short follow‑up phase.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

Participants in the study will be randomly assigned to receive either Sparsentan or an ARB. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will also include a period where participants can receive Sparsentan openly, allowing researchers to assess its long-term effects. Additionally, some participants may be involved in a sub-study to evaluate the combination of Sparsentan with another medication called Dapagliflozin, which is used to manage blood sugar levels in people with diabetes.

The trial will monitor changes in the amount of protein in the urine and kidney function over time. Participants will take the medication in tablet form by mouth. The study will last for several months, with regular check-ups to ensure the safety and effectiveness of the treatment. The goal is to gather information that could lead to better treatment options for people with IgAN.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

Participants in the study will receive either Satralizumab or a placebo. Satralizumab is administered as a subcutaneous injection, which means it is injected under the skin. The study will last for a period of 48 weeks, during which participants will be monitored for changes in their symptoms, such as a reduction in eye bulging and improvements in eye function and appearance. The study will also assess the safety of Satralizumab by monitoring any side effects that may occur.

In addition to Satralizumab, the study will also involve other medications, including Azathioprine, Mycophenolate Mofetil, Tocilizumab, Rituximab, Ciclosporin, and Glucocorticoids. These medications are commonly used to manage immune system activity and inflammation. The study aims to provide valuable information on the potential benefits and risks of using Satralizumab for treating Moderate-to-Severe Thyroid Eye Disease, helping to improve the quality of life for those affected by this condition.

Participants in the study will receive either eneboparatide or a placebo for a period of 24 weeks. The treatment is administered through a pre-filled pen for subcutaneous injection, which means it is injected under the skin. The goal is to evaluate how effective eneboparatide is in reducing the need for active vitamin D and oral calcium supplements, and in maintaining normal serum calcium levels. The study will also assess changes in symptoms and physical functioning of the participants.

In addition to eneboparatide, the study involves other medications such as calcitriol and calcium carbonate, which are commonly used to manage calcium levels. Another medication, alfacalcidol, is also part of the study. These medications are used to help understand the overall effectiveness of the new treatment. The study aims to provide valuable information on the safety and benefits of eneboparatide for people living with chronic hypoparathyroidism.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.

Participants in the study will receive a combination of medications. One group will take RO7771950 along with trastuzumab and capecitabine. The other group will receive tucatinib combined with trastuzumab and capecitabine. The trastuzumab may be given through an IV infusion, which is a liquid medicine delivered directly into a vein, or as a subcutaneous injection, which is administered just under the skin. The other medications are taken as an oral tablet by mouth.

During the study, medical professionals will monitor how the treatments affect the cancer and how the body responds over time. The research will look at how long the cancer stays stable without growing, a measure known as progression-free survival. Other aspects of the study include monitoring overall survival, how much the tumors shrink, and any side effects experienced during the treatment period.

Participants in the study may receive cagrilintide alone, the combination of cagrilintide and semaglutide, semaglutide alone, or a placebo. The study involves monitoring changes in Body Mass Index, which is a measurement used to determine if a person has a healthy weight for their height, and the BMI Standard Deviation Score, a calculation that compares a person’s body mass to the average for others of the same age and sex. The course of the study involves weekly injections over a period of time to observe how these substances affect body weight and overall health.

During the study, the way the body absorbs, distributes, and removes the medication will be examined. This process is known as pharmacokinetics. Researchers will look at how much of the drug remains in the blood and how much is removed through urine or during the blood cleaning process. The study will also monitor safety by observing vital signs and conducting various clinical tests.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The study aims to determine whether the combination of divarasib and pembrolizumab works better than the standard treatment combination in treating this type of lung cancer. The medications will be given through different routes – divarasib as tablets taken by mouth, while pembrolizumab, pemetrexed, carboplatin, and cisplatin are given through an intravenous infusion (through a vein).

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life and symptoms related to their cancer, such as cough and breathing difficulties. The study will measure how long patients live without their cancer getting worse and their overall survival time.

The purpose of the study is to determine if adding ficerafusp alfa to pembrolizumab works better than pembrolizumab with placebo for patients who have not received previous treatment for their advanced cancer. The study will test two different doses of ficerafusp alfa (750 mg and 1500 mg) to find the most effective and safest dose when combined with pembrolizumab.

During the treatment, participants will receive regular doses of the study medications for up to 24 months. The study will track how well the treatment works by measuring if the cancer shrinks or disappears (tumor response), how long patients live (overall survival), and how long patients live without their cancer getting worse (progression-free survival). The study will also monitor any side effects that participants may experience during treatment.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

Participants in the study will be randomly assigned to receive either the active medication or a placebo. The study is double-blind, meaning that neither the participants nor the researchers will know which specific treatment is being administered during the course of the trial. The process involves monitoring changes in Forced Vital Capacity, which is a measurement of the total amount of air a person can exhale from their lungs after taking a deep breath. The study will track these changes and other health factors over a period of time to see how the medication affects the progression of the disease.

During the study, researchers will monitor how the treatment affects the lungs, specifically looking at changes in Forced Vital Capacity, which is a measure of the total amount of air a person can exhale after taking a deep breath. The study also observes how the condition changes over time and examines the distance a person can walk during a 6-minute walk test, which is a common way to check physical fitness and lung function. The investigation will take place over a period of 52 weeks.

The purpose of the study is to assess how Dazodalibep affects the systemic manifestations, or widespread symptoms, of Sjögren’s Syndrome in participants who have moderate-to-severe disease activity. Participants in the study will receive either Dazodalibep or a placebo over a period of time, and their health will be monitored to observe any changes in their condition. The study will last for several weeks, and participants will undergo regular assessments to track their progress and any side effects they may experience.

Throughout the study, researchers will collect data on various health indicators, such as changes in disease activity scores and other symptoms related to Sjögren’s Syndrome. This information will help determine the potential benefits and risks of using Dazodalibep as a treatment option for this condition. The study is designed to provide valuable insights into the management of Sjögren’s Syndrome and to explore new possibilities for improving the quality of life for those affected by this disease.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

The purpose of the study is to compare how well DS-8201a works compared to standard chemotherapy in preventing the cancer from coming back. The study will look at how long participants remain free of disease after treatment. Participants will be randomly assigned to receive either DS-8201a or one of the standard chemotherapy combinations. All medications will be given through a vein as an infusion. The treatment period can last up to 51 cycles for DS-8201a or between 4 to 18 cycles for the standard chemotherapy options, depending on which treatment is assigned. A cycle is a repeating period of time during which the medication is given.

During the study, participants will have regular check-ups that include imaging scans to look for any signs of cancer returning, blood tests to check organ function and blood cell counts, heart function tests using ultrasound or similar scans, and eye examinations. The study will also measure how participants feel and their quality of life using questionnaires. The doctors will monitor for any side effects or unwanted reactions to the medications throughout the study. The study will also collect blood samples to measure the levels of the study medication in the body and to check if the body develops any immune response to the treatment.

The study is designed as a randomized, double-blind, placebo-controlled trial with an extension phase. This means that participants will be assigned by chance to receive either the study medication or placebo, and neither the participants nor the doctors will know which treatment is being given during the main part of the study. The study will involve adults between 18 and 45 years of age who have been diagnosed with Alport syndrome. Participants will need to have certain levels of kidney function and protein in their urine to take part. They will also need to be taking certain medications for their kidneys, specifically medicines known as ACE inhibitors or ARBs, which are commonly used to help protect the kidneys.

During the study, measurements will be taken to see how the treatment affects the amount of protein in the urine over time. The main focus will be on measuring the ratio of protein in the urine at specific time points during the treatment period, specifically at 16, 20, and 24 weeks. The study will also monitor participants for any unwanted effects or side effects that may occur during treatment. After the main treatment period, there will be an extension phase where participants may continue to be followed to gather more information about the long-term effects of the medication.

This is an extension study, which means it is designed for people who have already participated in and completed earlier studies of dazodalibep for Sjögren’s Syndrome. Those who join this study will continue to receive dazodalibep treatment for a longer time so that researchers can observe how safe the medication is when used over many months or years. The study will track any unwanted effects that occur during treatment, including any serious health problems that might develop. Researchers will also check if the body develops any immune responses against the medication by looking for anti-drug antibodies, which are proteins the body might make in reaction to the treatment.

Throughout the study, blood samples will be collected to measure the amount of dazodalibep in the bloodstream, which helps researchers understand how the medication moves through and stays in the body. The study is open-label, meaning both the participants and doctors will know that everyone is receiving the active medication rather than placebo. This long-term study allows researchers to gather important information about the ongoing safety of dazodalibep in people with Sjögren’s Syndrome over an extended treatment period.

The trial has two parts. The first part is a safety run-in phase where a small group of patients will receive BNT113 combined with pembrolizumab to check if the combination is safe and well-tolerated. The second part is a randomized phase where patients will be assigned by chance to receive either the combination of BNT113 and pembrolizumab or pembrolizumab alone. During the trial, doctors will monitor how the cancer responds to treatment and will check for any side effects. Patients will need to have regular visits, blood tests, and scans to see how well the treatment is working.

The trial will measure several outcomes including how long patients live, how long it takes before the cancer grows or spreads, and whether the cancer shrinks or disappears. Doctors will also carefully track any side effects that occur during treatment. The trial will use imaging scans to measure changes in tumor size and will follow patients for up to several years to gather information about the long-term effects of these treatments.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

People taking part in this study must be adults between 18 and 75 years old who have been diagnosed with dermatomyositis and have active muscle and skin disease. Participants should have received or be receiving treatment with corticosteroids, hydroxychloroquine, or other medicines that affect the immune system. The study will measure improvement using a scoring system that looks at different aspects of the disease, including muscle strength, skin condition, overall health as rated by both the doctor and the patient, ability to perform daily activities, and levels of certain enzymes in the blood that indicate muscle damage.

During the study, participants will take their assigned medicine by mouth in tablet form for up to 114 days. The study will track various measures of improvement at different time points, with the main assessment happening at week 52. These measures include changes in skin disease activity scores, the proportion of people who show moderate or major improvement, how quickly improvement occurs, and changes in the ability to carry out daily activities. The study will also look at whether participants can reduce their dose of prednisone or similar corticosteroid medicines while still showing improvement.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The purpose of the study is to compare how well the different treatment combinations work against the cancer. Participants will be randomly assigned to receive either the new combination with JNJ-61186372 or the standard treatment. During the study, doctors will monitor how the cancer responds to treatment and track how long participants live. They will also check for any side effects or problems that might occur with the treatments.

Throughout the study, participants will have regular check-ups where doctors will measure the size of the cancer using imaging scans and assess overall health. The study will also look at quality of life and symptoms by asking participants to complete questionnaires about how they are feeling and how the treatment affects their daily activities. Blood samples will be collected to measure medication levels in the body and to check for any immune responses to the treatment. The study will continue for several years to fully understand the long-term effects of these treatment combinations.

The purpose of this study is to find out how well the investigational treatment containing VH4524184 works in reducing the amount of virus in the blood compared to the approved treatment, and to check how safe these treatments are. The study will look at whether the amount of virus in the blood drops to very low levels and stays low during the treatment period. The study will also measure changes in certain blood cells that are important for the immune system and will check for any side effects that may occur during treatment.

People who join this study will be assigned to receive one of the treatment combinations and will take their assigned medicine for up to 24 months. During this time, they will have regular visits where blood samples will be collected to measure the amount of virus in the blood and to check their overall health. The study will monitor how well the treatment works and how people respond to it over time. The study is expected to start in early 2026 and continue until late 2028.